Almotriptan in the treatment of migraine

Neuropsychiatric Disease and Treatment

Volumn 3, Issue 6, 2007, Pages 799-809

  Sandrini, Giorgio ^a   Perrotta, Armando ^a   Arce Leal, Natalia L ^a   Buscone, Simona ^a   Nappi, Giuseppe ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

Almotriptan; Migraine; Treatment; Triptans

Indexed keywords

ALMOTRIPTAN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; ELETRIPTAN; ERGOTAMINE DERIVATIVE; FROVATRIPTAN; KETOCONAZOLE; MONOAMINE OXIDASE INHIBITOR; NARATRIPTAN; PLACEBO; RIZATRIPTAN; SEROTONIN 1B RECEPTOR; SEROTONIN 1D RECEPTOR; SEROTONIN UPTAKE INHIBITOR; SUMATRIPTAN; TRIPTAN DERIVATIVE; ZOLMITRIPTAN;

ARTICLE; BLOOD PRESSURE; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DOSE RESPONSE; DROWSINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG SPECIFICITY; DRUG TOLERABILITY; FATIGUE; HUMAN; LIPOPHILICITY; MAXIMUM PLASMA CONCENTRATION; MENSTRUAL MIGRAINE; MIGRAINE; MUSCLE FATIGUE; NAUSEA; NAUSEA AND VOMITING; NEUROGENIC INFLAMMATION; NOCICEPTION; NONHUMAN; PARESTHESIA; RECEPTOR AFFINITY; RECURRENCE RISK; RELAPSE; SEROTONINERGIC SYSTEM; SIDE EFFECT; SOMNOLENCE; THORAX PAIN; TRIGEMINAL NERVE; XEROSTOMIA;

EID: 38149128028     PISSN: 11766328     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (63)

1. Allais G, Acuto G, Cabarrocas X, et al. 2006. Efficacy and tolerability of almotriptan versus zolmitriptan for the acute treatment of menstrual migraine. Neurol Sci, 27(Suppl 2):S193-7.
2. Andlin-Sobocki P, Jonsson B, Wittchen HU, et al. 2005. Cost of disorders of the brain in Europe. Eur J Neurol, 12(Suppl 1): 1-27.
3. Bou J, Domenech T, Puig J, et al. 2000. Pharmacological characterization of almotriptan: an indolic 5-HT receptor agonist for the treatment of migraine. Eur J Pharmacol, 410:33-41.
4. Bou J, Gras J, Cortijo J, et al. 2001. Vascular effects of the new anti-migraine agent almotriptan on human cranial and peripheral arteries. Cephatalgia, 21:804-12.
5. Boyce M, Dunn K, Warrington S. 2001. Hemodynamic and electrocardiographic effects of almotriptan in healthy volunteers. J Cardiovasc Pharmacol, 37:280-9.
6. Buzzi MG, Moskowitz MA. 1990. The antimigraine drug sumatriptan (GR43175) selectively blocks neurogenic plasma extravasation from blood vessels in dura mater. Br J Pharmacol, 99:202-6.
7. Charles JA. 2006. Almotriptan in the acute treatment of migraine in patients 11-17 years old: an open-label pilot study of efficacy and safety. J Headache Pain, 7:95-7.
8. Colman SS, Brod MI, Krishnamurthy A, et al. 2001. Treatment satisfaction, functional status, and health-related quality of life of migraine patients treated with almotriptan or sumatriptan. Clin Ther, 23:127-45.
9. Dahlof C, Tfelt-Hansen P, Massiou H, et al. 2001. Dose-finding, placebo-controlled study of oral almotriptan in the acute treatment of migraine. Neurology, 57:1811-17.
10. Dahlof CG, Pascual J, Dodick DW, et al. 2006. Efficacy, speed of action and tolerability of almotriptan in the acute treatment of rnigraine: pooled individual patient data from four randomized, double-blind, placebo-controlled clinical trials. Cephalalgia, 26:400-8.
11. Dodick DW 2001. Oral almotriptan in the treatment of migraine: safety and tolerability. Headache, 41:449-55.
12. Dodick DW 2002. Almotriptan increases sustained pain-free outcomes in acute migraine: results from three controlled clinical trials. Headache, 42:21-7.
13. Dodick DW 2003. A review of the clinical efficacy and tolerability of almotriptan in acute migraine.Expert Opin Pharmacother, 4:1157-63. Review.
14. Dodick DW, Martin V. 2004. Triptans and CNS side-effects: pharmacokinetic and metabolic mechanisms. Cephalalgia, 24:417-24. Review.
15. Dodick DW, Sandrinj G, Williams P. 2007. Use of the sustained pain-free plus no adverse events endpoint in clinical trials of triptans in acute migraine. CNS Drugs, 21:73-82.
16. Dowson AJ, Massiou H, Lamez JM, et al. 2002. Almotriptan is an effective and well-tolerated treatment for migraine pain: results of a randomized, double-blind, placebo-controlled clinical trial. Cephalalgia, 22:453-61.
17. Dowson AJ, Massiou H, Lainez JM, et al. 2004. Almotriptan improves response rates when treatment is within 1 hour of migraine onset. Headache, 44:318-22.
18. Ferrari MD, Goadsby PJ, Roon KI, et al. 2002. Triptans (serotonin, 5-HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials. Cephalalgia, 22:633-58.
19. Ferrari MD, Roon KI, Lipton RB, et al. 2001. Oral triptans (serotonin 5-HT1B/1D agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet, 358:1668-75.
20. Fleishaker JC, Herman BD, Carel BJ, et al. 2003. Interaction between ketoconazole and almotriptan in healthy volunteers. J Clin Pharmacol, 43:423-7.
21. Fleishaker JC, Ryan KK, Carel BJ, et al. 2001. Evaluation of the potential pharmacokinetic interaction between almotriptan and fluoxetine in healthy volunteers. J Clin Pharmacol, 41:217-23.
22. Fleishaker JC, Ryan KK, Jansat JM, et al. 2001. Effect of MAO-A inhibition on the pharmacokinetics of almotriptan, an antimigraine agent in humans. Br J Clin Pharmacol, 51:437-41.
23. Fleishaker JC, Sisson TA, Carel BJ, et al. 2000. Pharmacokinetic interaction between verapamil and almotriptan in healthy volunteers. Clin Pharmacol Ther, 67:498-503.
24. Fleishaker JC, Sisson TA, Carel BJ, et al. 2001. Lack of pharmacokinetic interaction between the antimigraine compound, almotriptan, and propranolol in healthy volunteers. Cephalalgia, 21:61-5.
25. Gallagher RM, Kunkel R. 2003. Migraine medication attributes important for patient compliance: concerns about side effects may delay treatment. Headache, 43:36-43.
26. Goadsby PJ, Massiou H, Pascual J, et al. 2007. Almotriptan and zolmitriptan in the acute treatment of migraine. Acta Neurol Scand, 115:34-40.
27. Goadsby PJ, Zagami AS. 1991. Stimulation of the superior sagittal sinus increases metabolic activity and blood flow in certain regions of the brainstem and upper cervical spinal cord of the cat. Brain, 114:1001-11.
28. Gras J, Bou J, Llenas J, et al. 2000. Functional profile of almotriptan in animal models predictive of antimigraine activity. Eur J Pharmacol, 410:43-51.
29. Gras J, Llenas J, Jansat JM, et al. 2002. Almotriptan, a new anti-migraine agent: a review. CXS Drug Rev, 8:217-34. Review.
30. Hamalainen ML. 2006. Migraine in children and adolescents: a guide to drug treatment. CNS Drugs, 20:813-20. Review.
31. Headache Classification Subcommittee of the International Headache Society. 2004. The International Classification of Headache Disorders: 2nd edition. Cephalalgia, 24 (Suppl 1):9-160.
32. Hershey A, Powers SW, LeCates S, et al. 2001. Effectiveness of nasal sumatriptan in 5 to 12-year-old children. Headache, 41:693-7.
33. Hoskin KL, Lambert GA, Donaldson C, et al. 2004. The 5-hydroxytry ptamine1B/1D/1F receptor agonists eletriptan and naratriptan inhibit trigeminovascular input to the nucleus tractus solitarius in the cat. Brain Res, 998:91-9.
34. Hu. XH, Markson LE, Lipton RB, et al. 1999. Burden of migraine in the United States: disability and economic costs. Arch Intern Med, 159:813-18.
35. Jansat JM, Costa J, Salva P, et al. 2002. Absolute bioavailability, pharmacokinetics, and urinary excretion of the novel antimigraine agent almotriptan in healthy male volunteers. J Clin Pharmacol, 42:1303-10.
36. Jansat JM, Martinez-Tobed A, Garcia E, et al. 2006. Effect of food intake on the bioavailability of almotriptan, an antimigraine compound, in healthy volunteers: an open, randomized, crossover, single-dose clinical trial. Int J Clin Pharmacol Ther, 44:185-90.
37. Jhee SS, Shiovitz T, Crawford AW, et al. 2001. Pharmacokineties and pharmacodynamics of the triptan antimigraine agents: a comparative review. Clin Pharmacokinet, 40:189-205. Review.
38. Lainez M. 2004. Clinical benefits of early triptan therapy for migraine. Cephalalgia, 24(Suppl 2):24-30. Review.
39. Lipton RB, Bigal ME. 2005. Migraine: epidemiology, impact, and risk factors for progression. Headache, 45 (Suppl 1): S3-S13. Review.
40. Lipton RB, Hamelsky SW, Dayno JM. 2002. What do patients with migraine want from acute migraine treatment? Headache, 42(Suppl 1):3-9.
41. Lipton RB, Pan J. 2004. Is migraine a progressive brain disease? JAMA, 291:427-34.
42. Lipton RB, Stewart WF, Diamond S, et al. 2001. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache, 41:646-57.
43. Markowitz S, Saito K, Moskowitz MA. 1987. Neurogenically mediated leakage of plasma protein occurs from blood vessels in dura mater but not brain. J Neurosci, 7:4129-36.
44. Mathers CD, Stein C, Fat DM, et al. 2002. Global burden of disease 2000: version 2, methods and results. World Health Organization. URL: http://www.fic.nih.gov/dcpp/Ppts/gbdpaper.pdf.
45. Mathew NT, Firdayson G, Smith TR, et al. 2007. Early intervention with almotriptan: results of the AEGIS trial (AXERT((R)) early migraine intervention study). Headache, 47:189-98.
46. Mathew NT, 2003. Early intervention with almotriptan improves sustained pain-free response in acute migraine. Headache, 43:1075-9.
47. Mathew NT, Oral Almotriptan Study Group. 2002. A long-term open-label study of oral almotriptan 12.5 mg for the treatment of acute migraine. Headache, 42:32-40.
48. McEnroe JD, Fleishaker JG. 2005. Clinical pharmacokinetics of almotriptan, a serotonin 5-HT1B/1D receptor agonist for the treatment of migraine. Clin Pharmacokinet, 44:237-46.
49. Members of the task force, Evers S, Afra J, Frese A, et al. 2006. EFNS guideline on the drug treatment of migraine - report of an EFNS task force. Eur J Neurol, 13:560-72.
50. Mondell BE. 2003. A review of the effects of almotriptan and other triptans on clinical trial outcomes that are meaningful to patients with migraine. Clin Ther, 25:331-41. Review.
51. Moskowitz MA. 1990. Basic mechanisms in vascular headache. Neurol Clin, 8:801-15. Review.
52. Pascual J, Cabarrocas X. 2002. Within-patient early versus delayed treatment of migraine attacks with almotriptan: the sooner the better. Headache, 42:28-31.
53. Pascual J, Falk M, Piessens F, et al. 2000. Consistent efficacy and tolerability of almotriptan in the acute treatment of multiple migraine attacks: results of a large, randomized, double-blind, placebo-controlled study. Cephalalgia, 20:588-96.
54. Sandrini G, Dahl6f CG, Mathew N, et al. 2005. Focus on trial endpoints of clinical relevance and the use of almotriptan for the acute treatment of migraine. Int J Clin Pract, 59:1356-65.
55. Santanello NC, Davies G, Allen C, et al. 2002. Determinants of migraine-specific quality of life. Cephalalgia, 22:680-5.
56. Silberstein SD. 2000. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology, 55:754-62.
57. Spierings EL, Gomez-Mancilla B, Grosz DE, et al. 2001. Oral almotriptan versus oral sumatriptan in the abortive treatment of migraine: a double-blind, randomized, parallel-group, optimum-dose comparison. Arch Neurol, 58:944-50.
58. Storer RJ, Goadsby PJ. 1997. Microiontophoretic application of serotonin (5HT)1B/1D agonists inhibitstrigerninal cell firing in the cat. Brain, 120:2171-7.
59. Stovner LJ, Zwart JA, Hagen K et al. 2006. Epidemiology of headache in Europe. Eur J Neurol, 13:333-45. Review.
60. Tfelt-Hansen P, Block G, Dahlof C, et al. 2000. International Headache Society Clinical Trials Subcommittee. Guidelines for controlled trials of drugs in migraine: second edition. Cephalalgia, 20:765-86.
61. Tfelt-Hansen P, De Vries P, Saxena PR. 2000. Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy. Drugs, 60:1259-87. Review.
62. Winner P, Lewis D, Visser WH, et al. 2002. Rizatriptan 5 mg for the acute treatment of migraine in adolescents: a randomized double-blind, placebo-controlled study. Headache, 42:49-55.
63. Yu X-J, Waeber C, Castanon N, et al. 1996. 5-carboxamido- tryptarnine CP-122,288 and dihydroergotamine but not sumatriptan CP-93, 129 and serotonin-5-O-carboxytnethyl-glycyl-tyrosinamide block dural plasma protein extravasation in knockout mice that lack 5-hydroxytryptamine1B receptors. Mol Pharmacol, 49:761-5.